Shares of Oncobiologics Inc (NASDAQ:ONS) have received an average broker rating score of 3.00 (Hold) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation. Oncobiologics’ rating score has declined by 200% from 90 days ago as a result of a number of analysts’ ratings changes.
Zacks has also given Oncobiologics an industry rank of 183 out of 265 based on the ratings given to related companies.
A number of brokerages have recently issued reports on ONS. ValuEngine raised Oncobiologics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Barclays lowered Oncobiologics from an “overweight” rating to an “equal weight” rating in a research report on Monday, January 29th.
Oncobiologics (NASDAQ:ONS) last announced its earnings results on Wednesday, February 14th. The company reported ($0.28) earnings per share (EPS) for the quarter. The firm had revenue of $0.77 million during the quarter.
Oncobiologics Company Profile
Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.